177 results on '"Shaefer, Mark S."'
Search Results
2. HLA-B*57:01 screening and hypersensitivity reaction to abacavir between 1999 and 2016 in the OPERA® observational database: a cohort study
3. Are We Hitting the Target? HIV Pre-Exposure Prophylaxis from 2012 to 2020 in the OPERA Cohort
4. Investigating New Antiretroviral Combinations [with Reply to Carr]
5. Early Virologic Nonresponse to Tenofovir, Abacavir, and Lamivudine in HIV-Infected Antiretroviral-Naive Subjects
6. Twice-Daily Triple Nucleoside Intensification Treatment with Lamivudine-Zidovudine plus Abacavir Sustains Suppression of Human Immunodeficiency Virus Type 1: Results of the TARGET Study
7. Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M)
8. To dose-adjust or not to dose-adjust: lamivudine dose in kidney impairment
9. Simplification to abacavir/lamivudine (ABC/3TC) + atazanavir (ATV) from tenofovir/emtricitabine (TDF/FTC) + ATV/ritonavir (r) maintains viral suppression and improves bone biomarkers: 48 weeks ASSURE study results.: 98E.
10. Long-term results of initial therapy with abacavir and lamivudine combined with efavirenz, amprenavir/ritanovir, or stavudine
11. Impact of an educational program on efficacy and adherence with a twice-daily Lamivudine/Zidovudine/Abicavir regimen in underrepresented HIV-infected patients
12. 106E. Prevalence of HIV-associated neurocognitive disorders (HAND) in virologically suppressed HIV-infected individuals in the ASSURE (EPZ113734) study versus non-HIV-infected control subjects.
13. Correlation between self-reported adherence to highly active antiretroviral therapy (HAART) and virologic outcome
14. ARIES 144 Week Results: Durable Virologic Suppression in HIV-Infected Patients Simplified to Unboosted Atazanavir/Abacavir/Lamivudine
15. Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients
16. Changes over time in creatinine clearance and comparison of emergent adverse events for HIV-positive adults receiving standard doses (300 mg/day) of lamivudine-containing antiretroviral therapy with baseline creatinine clearance of 30–49 vs ≥50 mL/min
17. 2497. Women’s Perspectives on and Experiences with Long-acting Injectable Anti-retroviral Therapy in the United States and Spain: the Potential Role of Gender in Patient Preferences
18. 884. Patient Adherence to Long-Acting Injectable Cabotegravir + Rilpivirine Through 48 Weeks of Maintenance Therapy in the Phase 3 ATLAS and FLAIR Studies
19. Safety and Efficacy of a 36-Week Induction Regimen of Abacavir/Lamivudine and Ritonavir-Boosted Atazanavir in HIV-Infected Patients
20. Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment
21. Short-term Safety and Tolerability of a Once-Daily Fixed-Dose Abacavir-Lamivudine Combination versus Twice-Daily Dosing of Abacavir and Lamivudine as Separate Components: Findings from the ALOHA Study
22. Pilot Study of Once-Daily Simplification Therapy with Abacavir/Lamivudine/Zidovudine and Efavirenz for Treatment of HIV-1 Infection
23. Maintenance with trizivir (TZV) or TZV + efavirenz (EFV) for 48 weeks following a 48-week induction with TZV + EFV in antiretroviral-naive HIV-1 infected subjects (ESS40013).: 147E.
24. Quadruple nucleoside/tide regimen of Trizivir (TZV) + Tenofovir (TDF) is effective following early virologic failure on an initial regimen containing a thymidine analog + lamivudine in combination with a protease inhibitor (PI) or non-nucleoside reverse t: 146E.
25. Efficacy and safety of once-daily abacavir/lamivudine fixed-dose combination (ABC/3TC) + efavirenz (EFV): ESS30009 planned 48 week analysis.: 150E.
26. Abacavir + lamivudine fixed dose combination tablet once daily (QD) compared with abacavir (ABC) and lamivudine (3TC) twice daily (BID) in HIV-1 infected subjects (ESS30008).: 144E.
27. Efficacy, safety, and adherence with a twice-daily combination lamivudine/zidovudine tablet formulation, plus a protease inhibitor, in HIV infection
28. Comparison of adherence to Combivir® and abacavir in the H.E.A.R.T. (helping to enhance adherence to antiretroviral therapy) trial using MEMS® Trackcaps™.: 78.
29. Abacavir Hypersensitivity Reaction Reporting Rates During a Decade ofHLA‐B*5701 Screening as a Risk‐Mitigation Measure
30. Similar neurocognitive outcomes after 48 weeks in HIV-1-infected participants randomized to continue tenofovir/emtricitabine + atazanavir/ritonavir or simplify to abacavir/lamivudine + atazanavir
31. Preliminary data of effective switch/intensification treatment with Combivir®, and Ziagen®, in therapy-experienced adults.: 92E.
32. 101. HIV viral load response to triple combination therapy in the Pacific Oaks Population Study.
33. A randomized, controlled trial of initial anti-retroviral therapy with abacavir/lamivudine/zidovudine twice-daily compared to atazanavir once-daily with lamivudine/zidovudine twice-daily in HIV-infected patients over 48 weeks (ESS100327, the ACTION Study)
34. Clinical spectrum of fungal infections after orthotopic liver transplantation
35. Changes from 2000 to 2009 in the Prevalence of HIV-1 Containing Drug Resistance-Associated Mutations from Antiretroviral Therapy-Naive, HIV-1-Infected Patients in the United States
36. HLA-B*57:01 allele prevalence in HIV-infected North American subjects and the impact of allele testing on the incidence of abacavir-associated hypersensitivity reaction in HLA-B*57:01-negative subjects
37. Abacavir Use and Risk for Myocardial Infarction and Coronary Artery Disease: Updated Meta-analysis of Data from Clinical Trials
38. Abacavir Hypersensitivity Reaction Reporting Rates During a Decade of HLA‐B*5701 Screening as a Risk‐Mitigation Measure.
39. Estimated glomerular filtration rates through 144 weeks on therapy in HIV-1-infected subjects receiving atazanavir/ritonavir and abacavir/lamivudine or simplified to unboosted atazanavir/abacavir/lamivudine
40. How clean was the KLEAN trial?
41. Response by gender of HIV-1-infected subjects treated with abacavir/lamivudine plus atazanavir, with or without ritonavir, for 144 weeks.
42. Simplification to Abacavir/Lamivudine + Atazanavir Maintains Viral Suppression and Improves Bone and Renal Biomarkers in ASSURE, a Randomized, Open Label, Non-Inferiority Trial
43. HIV-1 Transmission Patterns in Antiretroviral Therapy-Naïve, HIV-Infected North Americans Based on Phylogenetic Analysis by Population Level and Ultra-Deep DNA Sequencing
44. Prolonged Paralysis Associated with Long-Term Pancuronium Use
45. A randomized, controlled trial of initial anti-retroviral therapy with abacavir/lamivudine/zidovudine twice-daily compared to atazanavir once-daily with lamivudine/zidovudine twice-daily in HIV-infected patients over 48 weeks (ESS100327, the ACTION Study)
46. Clinical patterns of cytomegalovirus disease after liver transplantation
47. How clean was the KLEAN trial? – Authors' reply
48. Reply to Carr
49. Abacavir/Lamivudine/Zidovudine Continues to be a Valid and Useful Antiretroviral Regimen
50. Pharmacodynamic Effects of Zidovudine 600 mg Once/Day versus 300 mg Twice/Day in Therapy-Naïve Patients Infected with Human Immunodeficiency Virus
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.